[1]

GBD 2017 DALYs and HALE Collaborators. 2018. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990−2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392:1859−922

doi: 10.1016/S0140-6736(17)32130-X
[2]

Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, et al. 2019. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. The Lancet 394:240−48

doi: 10.1016/S0140-6736(19)30934-1
[3]

James SL, Abate D, Abate KH, Abay SM, Abbafati C, et al. 2018. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392:1789−858

doi: 10.1016/S0140-6736(18)32279-7
[4]

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. 2016. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990−2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 388:1545−602

doi: 10.1016/S0140-6736(16)31678-6
[5]

Tham YC, Li X, Wong TY, Quigley HA, Aung T, et al. 2014. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081−90

doi: 10.1016/j.ophtha.2014.05.013
[6]

Zheng C, Zeng R, Wu G, Hu Y, Yu H. 2024. Beyond vision: a view from eye to Alzheimer's disease and dementia. The Journal of Prevention of Alzheimer's Disease 11:469−83

doi: 10.14283/jpad.2023.118
[7]

Tham YC, Cheng CY. 2017. Associations between chronic systemic diseases and primary open angle glaucoma: an epidemiological perspective. Clinical & Experimental Ophthalmology 45:24−32

doi: 10.1111/ceo.12763
[8]

Trouilloud A, Ferry E, Boucart M, Kauffmann L, Warniez A, et al. 2023. Impact of glaucoma on the spatial frequency processing of scenes in central vision. Visual Neuroscience 40:E001

doi: 10.1017/S0952523822000086
[9]

Zheng C, Liu S, Zhang X, Hu Y, Shang X, et al. 2022. Shared genetic architecture between the two neurodegenerative diseases: Alzheimer's disease and glaucoma. Frontiers in Aging Neuroscience 14:880576

doi: 10.3389/fnagi.2022.880576
[10]

Jampel HD, Frick KD, Janz NK, Wren PA, Musch DC, et al. 2007. Depression and mood indicators in newly diagnosed glaucoma patients. American Journal of Ophthalmology 144:238−244.e1

doi: 10.1016/j.ajo.2007.04.048
[11]

Prager AJ, Liebmann JM, Cioffi GA, Blumberg DM. 2016. Self-reported function, health resource use, and total health care costs among Medicare beneficiaries with glaucoma. JAMA Ophthalmology 134:357−65

doi: 10.1001/jamaophthalmol.2015.5479
[12]

Zhu MM, Lai JSM, Choy BNK, Shum JWH, Lo ACY, et al. 2018. Physical exercise and glaucoma: a review on the roles of physical exercise on intraocular pressure control, ocular blood flow regulation, neuroprotection and glaucoma-related mental health. Acta Ophthalmologica 96:e676−e691

doi: 10.1111/aos.13661
[13]

Çakmak H, Altinyazar V, Yilmaz SG, Ömürlü İK, Kocatürk T, et al. 2015. The temperament and character personality profile of the glaucoma patient. BMC Ophthalmology 15:125

doi: 10.1186/s12886-015-0117-9
[14]

Saeedi O, Ashraf H, Malouf M, Slade EP, Medoff DR, et al. 2016. Prevalence of diagnosed ocular disease in veterans with serious mental illness. General Hospital Psychiatry 43:1−5

doi: 10.1016/j.genhosppsych.2016.08.003
[15]

Smith D, Pantelis C, McGrath J, Tangas C, Copolov D. 1997. Ocular abnormalities in chronic schizophrenia: clinical implications. Australian and New Zealand Journal of Psychiatry 31:252−56

doi: 10.3109/00048679709073828
[16]

Liu CH, Kang EY, Lin YH, Wu WC, Liu ZH, et al. 2020. Association of ocular diseases with schizophrenia, bipolar disorder, and major depressive disorder: a retrospective case-control, population-based study. BMC Psychiatry 20:486

doi: 10.1186/s12888-020-02881-w
[17]

Zhang X, Olson DJ, Le P, Lin FC, Fleischman D, et al. 2017. The association between glaucoma, anxiety, and depression in a large population. American Journal of Ophthalmology 183:37−41

doi: 10.1016/j.ajo.2017.07.021
[18]

Mabuchi F, Yoshimura K, Kashiwagi K, Shioe K, Yamagata Z, et al. 2008. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. Journal of Glaucoma 17:552−57

doi: 10.1097/IJG.0b013e31816299d4
[19]

Wang SY, Singh K, Lin SC. 2012. Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. American Journal of Ophthalmology 154:436−444.e2

doi: 10.1016/j.ajo.2012.03.039[LinkOut]
[20]

Yochim BP, Mueller AE, Kane KD, Kahook MY. 2012. Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. Journal of Glaucoma 21:250−54

doi: 10.1097/IJG.0b013e3182071b7e
[21]

Groff ML, Choi B, Lin T, Mcllraith I, Hutnik C, et al. 2023. Anxiety, depression, and sleep-related outcomes of glaucoma patients: systematic review and meta-analysis. Canadian Journal of Ophthalmology 58:346−55

doi: 10.1016/j.jcjo.2022.02.010
[22]

Zheng Y, Wu X, Lin X, Lin H. 2017. The prevalence of depression and depressive symptoms among eye disease patients: a systematic review and meta-analysis. Scientific Reports 7:46453

doi: 10.1038/srep46453
[23]

Berchuck S, Jammal A, Mukherjee S, Somers T, Medeiros FA. 2021. Impact of anxiety and depression on progression to glaucoma among glaucoma suspects. British Journal of Ophthalmology 105:1244−49

doi: 10.1136/bjophthalmol-2020-316617
[24]

Owen MJ, Sawa A, Mortensen PB. 2016. Schizophrenia. The Lancet 388:86−97

doi: 10.1016/S0140-6736(15)01121-6
[25]

Sullivan PF, Daly MJ, O'Donovan M. 2012. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nature Reviews Genetics 13:537−51

doi: 10.1038/nrg3240
[26]

O'Donovan MC, Owen MJ. 2016. The implications of the shared genetics of psychiatric disorders. Nature Medicine 22:1214−19

doi: 10.1038/nm.4196
[27]

Shimada-Sugimoto M, Otowa T, Hettema JM. 2015. Genetics of anxiety disorders: Genetic epidemiological and molecular studies in humans. Psychiatry and Clinical Neurosciences 69:388−401

doi: 10.1111/pcn.12291
[28]

Thapar A. 2018. Discoveries on the genetics of ADHD in the 21st century: new findings and their implications. The American Journal of Psychiatry 175:943−50

doi: 10.1176/appi.ajp.2018.18040383
[29]

Gharahkhani P, Jorgenson E, Hysi P, Khawaja AP, Pendergrass S, et al. 2021. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. Nature Communications 12:1258

doi: 10.1038/s41467-020-20851-4
[30]

Gharahkhani P, Burdon KP, Fogarty R, Sharma S, Hewitt AW, et al. 2014. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. Nature Genetics 46:1120−25

doi: 10.1038/ng.3079
[31]

Craig JE, Han X, Qassim A, Hassall M, Cooke Bailey JN, et al. 2020. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nature Genetics 52:160−66

doi: 10.1038/s41588-019-0556-y
[32]

Davey Smith G, Hemani G. 2014. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Human Molecular Genetics 23:R89−R98

doi: 10.1093/hmg/ddu328
[33]

Davies NM, Holmes MV, Davey Smith G. 2018. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362:k601

doi: 10.1136/bmj.k601
[34]

Sekula P, Fabiola Greco M, Pattaro C, Köttgen A. 2016. Mendelian randomization as an approach to assess causality using observational data. Journal of the American Society of Nephrology 27:3253−65

doi: 10.1681/ASN.2016010098
[35]

Evans DM, Davey Smith G. 2015. Mendelian randomization: new applications in the coming age of hypothesis-free causality. Annual Review of Genomics and Human Genetics 16:327−50

doi: 10.1146/annurev-genom-090314-050016
[36]

Holmes MV, Ala-Korpela M, Smith GD. 2017. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nature Reviews Cardiology 14:577−90

doi: 10.1038/nrcardio.2017.78
[37]

Arsenault BJ. 2022. From the garden to the clinic: how Mendelian randomization is shaping up atherosclerotic cardiovascular disease prevention strategies. European Heart Journal 43:4447−49

doi: 10.1093/eurheartj/ehac394
[38]

Smith GD, Ebrahim S. 2004. Mendelian randomization: prospects, potentials, and limitations. International Journal of Epidemiology 33:30−42

doi: 10.1093/ije/dyh132
[39]

Hou L, Bergen SE, Akula N, Song J, Hultman CM, et al. 2016. Genome-wide association study of 40, 000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics 25:3383−94

doi: 10.1093/hmg/ddw181
[40]

Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421−27

doi: 10.1038/nature13595
[41]

Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, et al. 2019. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics 51:63−75

doi: 10.1038/s41588-018-0269-7
[42]

Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, et al. 2023. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613:508−18

doi: 10.1038/s41586-022-05473-8
[43]

Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, et al. 2019. PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations. Bioinformatics 35:4851−53

doi: 10.1093/bioinformatics/btz469
[44]

Burgess S, Butterworth A, Thompson SG. 2013. Mendelian randomization analysis with multiple genetic variants using summarized data. Genetic Epidemiology 37:658−65

doi: 10.1002/gepi.21758
[45]

Bowden J, Davey Smith G, Burgess S. 2015. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology 44:512−25

doi: 10.1093/ije/dyv080
[46]

Bowden J, Davey Smith G, Haycock PC, Burgess S. 2016. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genetic Epidemiology 40:304−14

doi: 10.1002/gepi.21965
[47]

Hartwig FP, Davey Smith G, Bowden J. 2017. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. International Journal of Epidemiology 46:1985−98

doi: 10.1093/ije/dyx102
[48]

Fabiola Greco M, Minelli C, Sheehan NA, Thompson JR. 2015. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Statistics in Medicine 34:2926−40

doi: 10.1002/sim.6522
[49]

Verbanck M, Chen CY, Neale B, Do R. 2018. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics 50:693−98

doi: 10.1038/s41588-018-0099-7
[50]

Guo J, Yu K, Dong SS, Yao S, Rong Y, et al. 2022. Mendelian randomization analyses support causal relationships between brain imaging-derived phenotypes and risk of psychiatric disorders. Nature Neuroscience 25:1519−27

doi: 10.1038/s41593-022-01174-7
[51]

Yang Y, Musco H, Simpson-Yap S, Zhu Z, Wang Y, et al. 2021. Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. Nature Communications 12:5641

doi: 10.1038/s41467-021-25768-0
[52]

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, et al. 2018. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7:e34408

doi: 10.7554/eLife.34408
[53]

Soh Z, Yu M, Betzler BK, Majithia S, Thakur S, et al. 2021. The global extent of undetected glaucoma in adults: a systematic review and meta-analysis. Ophthalmology 128:1393−404

doi: 10.1016/j.ophtha.2021.04.009
[54]

Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, et al. 2017. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. The Lancet Global Health 5:e1221−e1234

doi: 10.1016/S2214-109X(17)30393-5
[55]

Shin DY, Jung KI, Park HYL, Park CK. 2021. The effect of anxiety and depression on progression of glaucoma. Scientific Reports 11:1769

doi: 10.1038/s41598-021-81512-0
[56]

Silverstein SM, Choi JJ, Green KM, Bowles-Johnson KE, Ramchandran RS. 2022. Schizophrenia in translation: why the eye? Schizophrenia Bulletin 48:728−37

doi: 10.1093/schbul/sbac050
[57]

Appaji A, Nagendra B, Chako DM, Padmanabha A, Jacob A, et al. 2019. Examination of retinal vascular trajectory in schizophrenia and bipolar disorder. Psychiatry and Clinical Neurosciences 73:738−44

doi: 10.1111/pcn.12921
[58]

Adhan I, Bannai D, Lizano P. 2020. Commentary: can retinal imaging biomarkers inform psychosis pathophysiology? Schizophrenia Research 215:3−5

doi: 10.1016/j.schres.2019.10.020
[59]

Asanad S, O'Neill H, Addis H, Chen S, Wang J, et al. 2021. Neuroretinal biomarkers for schizophrenia spectrum disorders. Translational Vision Science & Technology 10:29

doi: 10.1167/tvst.10.4.29
[60]

Mitchell P, Leung H, Wang JJ, Rochtchina E, Lee AJ, et al. 2005. Retinal vessel diameter and open-angle glaucoma: the Blue Mountains Eye Study. Ophthalmology 112:245−50

doi: 10.1016/j.ophtha.2004.08.015
[61]

Allen JA, Yadav PN, Setola V, Farrell M, Roth BL. 2011. Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo. Translational Psychiatry 1:e33

doi: 10.1038/tp.2011.35
[62]

Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320:539−43

doi: 10.1126/science.1155174
[63]

Thorleifsson G, Walters GB, Hewitt AW, Masson G, Helgason A, et al. 2010. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nature Genetics 42:906−9

doi: 10.1038/ng.661
[64]

Loomis SJ, Kang JH, Weinreb RN, Yaspan BL, Cooke Bailey JN, et al. 2014. Association of CAV1/CAV2 genomic variants with primary open-angle glaucoma overall and by gender and pattern of visual field loss. Ophthalmology 121:508−16

doi: 10.1016/j.ophtha.2013.09.012
[65]

Park SC, De Moraes CG, Teng CCW, Tello C, Liebmann JM, et al. 2011. Initial parafoveal versus peripheral scotomas in glaucoma: risk factors and visual field characteristics. Ophthalmology 118:1782−89

doi: 10.1016/j.ophtha.2011.02.013
[66]

Boudriot E, Stephan M, Rabe F, Smigielski L, Schmitt A, et al. 2025. Genetic analysis of retinal cell types in neuropsychiatric disorders. JAMA Psychiatry 82:285−95

doi: 10.1001/jamapsychiatry.2024.4230
[67]

Wagner SK, Cortina-Borja M, Silverstein SM, Zhou Y, Romero-Bascones D, et al. 2023. Association between retinal features from multimodal imaging and schizophrenia. JAMA Psychiatry 80:478−87

doi: 10.1001/jamapsychiatry.2023.0171
[68]

Martínez-Pinteño A, Mezquida G, Bioque M, López-Ilundain JM, Andreu-Bernabeu Á, et al. 2022. The role of BDNF and NGF plasma levels in first-episode schizophrenia: a longitudinal study. European Neuropsychopharmacology 57:105−17

doi: 10.1016/j.euroneuro.2022.02.003
[69]

Galindo-Romero C, Valiente-Soriano FJ, Jiménez-López M, García-Ayuso D, Villegas-Pérez MP, et al. 2013. Effect of brain-derived neurotrophic factor on mouse axotomized retinal ganglion cells and phagocytic microglia. Investigative Ophthalmology & Visual Science 54:974−85

doi: 10.1167/iovs.12-11207
[70]

Zhang J, Chen X, Zhu Y, Wan S, Hu S, Yang Y. 2024. Investigating the causal relationship between sleep behaviors and primary open-angle glaucoma: a bidirectional two-sample Mendelian randomization study. Nature and Science of Sleep 16:143−53

doi: 10.2147/NSS.S439274
[71]

Kimmel PL, Thamer M, Richard CM, Ray NF. 1998. Psychiatric illness in patients with end-stage renal disease. The American Journal of Medicine 105:214−21

doi: 10.1016/S0002-9343(98)00245-9
[72]

Clarke DM, Currie KC. 2009. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. The Medical Journal of Australia 190:S54−S60

doi: 10.5694/j.1326-5377.2009.tb02274.x
[73]

Warrian KJ, Spaeth GL, Lankaranian D, Lopes JF, Steinmann WC. 2009. The effect of personality on measures of quality of life related to vision in glaucoma patients. British Journal of Ophthalmology 93:310−15

doi: 10.1136/bjo.2008.139592
[74]

Wilson MR, Coleman AL, Yu F, Fong Sasaki I, Bing EG, et al. 2002. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology 109:1018−22

doi: 10.1016/S0161-6420(02)00993-4
[75]

Tueth MJ. 1994. Emergencies caused by side effects of psychiatric medications. The American Journal of Emergency Medicine 12:212−16

doi: 10.1016/0735-6757(94)90248-8
[76]

Ciobanu AM, Dionisie V, Neagu C, Bolog OM, Riga S, et al. 2021. Psychopharmacological treatment, intraocular pressure and the risk of glaucoma: a review of literature. Journal of Clinical Medicine 10:2947

doi: 10.3390/jcm10132947